No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
QGEN240517C40000
- 4.10
- +0.60+17.14%
15min DelayClose May 13 12:39 ET
4.10High4.10Low
4.10Open3.50Pre Close2 Volume55 Open Interest40.00Strike Price820.00Turnover55.13%IV0.16%PremiumMay 17, 2024Expiry Date4.33Intrinsic Value100Multiplier4DDays to Expiry0.00Time Value100Contract SizeAmericanOptions Type0.9594Delta0.0326Gamma10.08Leverage Ratio-0.0289Theta0.0046Rho9.67Eff Leverage0.0042Vega
Intraday
- 5D
- 1D
News
QIAGEN Gets FDA Clearance for QIAstat-Dx Respiratory Panel Plus
Qiagen's (NYSE:QGEN) Investors Will Be Pleased With Their 15% Return Over the Last Five Years
If you buy and hold a stock for many years, you'd hope to be making a profit. Furthermore, you'd generally like to see the share price rise faster than the market. Unfortunately for shareholders, wh
Qiagen Obtains US FDA Clearance for Respiratory Syndromic Testing Panel
Qiagen (QIA.F) on Monday said the US Food and Drug Administration authorized its QIAstat-Dx respiratory syndromic testing panel for clinical use. The molecular testing company's QIAstat-Dx Respiratory
Express News | NYSE Order Imbalance 92847.0 Shares on Buy Side
Express News | NYSE Order Imbalance 58834.0 Shares on Buy Side
QIAGEN Partners With FBI to Develop Digital PCR Assay for QIAcuity for Use in Forensics
Collaboration aims to create novel digital PCR assay to improve successful results in DNA analysis from human samples for use in forensics and human identification // DNA quantification enables law en
Comments
Qiagen's high P/E ratio is worrisome due to its poor earnings forecast. Despite the high P/E, investors retain their shares, but this earnings growth rate may eventually impact the share price. The high P/E and future earnings predictions pose a substantial risk to shareholders and potential investors.
There's Reason For Concern Over Qiagen N.V.'s (NYSE:QGEN) PriceQiagen's performance is strong due to strategic profit reinvestment, leading to significant earnings growth. Its respectable ROE contributes to a net income increase. Yet, forecasts anticipate a slowdown in future earnings growth.
2
Here are the top gap ups and downs for the stocks with a market cap above $5 billion after the previous market closed (gaps range from large to small):
Gap Ups
1. $SolarEdge Technologies(SEDG.US$ - up 7.31%
2. $Kohl's Corp(KSS.US$ - up 4.46%
3. $DuPont(DD.US$ - up 4.38%
4. $Welltower Inc(WELL.US$ - up 4.02%
5. $CNH Industrial(CNHI.US$ - up 3.18%
6. $Planet Fitness(PLNT.US$ - up 3.46%
7. $Qiagen NV(QGEN.US$ - up 2.35%
8. $Taiwan Semiconductor(TSM.US$ - up 2.05...
Gap Ups
1. $SolarEdge Technologies(SEDG.US$ - up 7.31%
2. $Kohl's Corp(KSS.US$ - up 4.46%
3. $DuPont(DD.US$ - up 4.38%
4. $Welltower Inc(WELL.US$ - up 4.02%
5. $CNH Industrial(CNHI.US$ - up 3.18%
6. $Planet Fitness(PLNT.US$ - up 3.46%
7. $Qiagen NV(QGEN.US$ - up 2.35%
8. $Taiwan Semiconductor(TSM.US$ - up 2.05...
+17
18
Gapping up
$Qiagen NV(QGEN.US$ +3.4% (the biotech company raised its full-year outlook, pointing to particular strength in its non-Covid product portfolio.)
$Lordstown Motors(RIDE.US$ +14.6% (contract manufacturer Foxconn will invest up to $170 million in the electric vehicle maker and become its largest shareholder.)
$DuPont(DD.US$ +3.7% (the industrial materials maker beat top and bottom line estimates for the third quarter. Du...
$Qiagen NV(QGEN.US$ +3.4% (the biotech company raised its full-year outlook, pointing to particular strength in its non-Covid product portfolio.)
$Lordstown Motors(RIDE.US$ +14.6% (contract manufacturer Foxconn will invest up to $170 million in the electric vehicle maker and become its largest shareholder.)
$DuPont(DD.US$ +3.7% (the industrial materials maker beat top and bottom line estimates for the third quarter. Du...
9
1
Read more